Literature DB >> 19109449

Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9.

Christoph Georg Baums1, Christoph Kock, Andreas Beineke, Katharina Bennecke, Ralph Goethe, Charlotte Schröder, Karl-Heinz Waldmann, Peter Valentin-Weigand.   

Abstract

Streptococcus suis causes numerous diseases in pigs, most importantly, meningitis, arthritis, septicemia, and bronchopneumonia. One of the major problems in modern swine production is the lack of a vaccine protecting against more than one S. suis serotype. The objective of this study was to determine the protective efficacy of a serotype 2 murein-associated protein (MAP) fraction subunit vaccine in comparison to that of a bacterin against experimental challenge with serotype 2 (containing muramidase-released protein [MRP], extracellular factor, and suilysin [SLY]) and serotype 9 (containing MRP variant MRP* and SLY) strains. MAP was shown to include different surface-associated proteins, such as the MRP and surface antigen one (SAO) expressed by both pathotypes used for challenge. The results of this study demonstrated that the serotype 2 bacterin induced protective immunity against homologous challenge. In contrast, the protective efficacy of the MAP subunit vaccine was low, though MAP immunization resulted in high serum immunoglobulin G2 titers against MRP and SAO. Importantly, immunization with bacterin but not with MAP induced opsonizing antibody titers against the serotype 2 strain, and these antibody titers were found to correlate with protection. However, after absorption with a nonencapsulated isogenic mutant, the sera from bacterin-immunized piglets failed to facilitate neutrophil killing, indicating that antibodies directed against capsule may not have been essential for opsonophagocytosis. Furthermore, induction of opsonizing antibodies against serotype 9 was not detectable in the group receiving bacterin or in the group receiving the MAP vaccine. In agreement, protection against the heterologous serotype 9 strain was low in both groups. Thus, identification of an antigen protecting against these two important S. suis pathotypes remains an important goal of future studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109449      PMCID: PMC2643536          DOI: 10.1128/CVI.00371-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  22 in total

Review 1.  Efficacy of vaccines against bacterial diseases in swine: what can we expect?

Authors:  Freddy Haesebrouck; Frank Pasmans; Koen Chiers; Dominiek Maes; Richard Ducatelle; Annemie Decostere
Journal:  Vet Microbiol       Date:  2004-06-03       Impact factor: 3.293

2.  Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European countries.

Authors:  H J Wisselink; H E Smith; N Stockhofe-Zurwieden; K Peperkamp; U Vecht
Journal:  Vet Microbiol       Date:  2000-06-01       Impact factor: 3.293

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.

Authors:  R S Baltimore; D L Kasper; C J Baker; D K Goroff
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

5.  Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis serotype 2.

Authors:  Henk J Wisselink; Norbert Stockhofe-Zurwieden; Luuk A T Hilgers; Hilde E Smith
Journal:  Vet Microbiol       Date:  2002-01-03       Impact factor: 3.293

6.  Contribution of fibronectin-binding protein to pathogenesis of Streptococcus suis serotype 2.

Authors:  Astrid de Greeff; Herma Buys; Robin Verhaar; Janny Dijkstra; Loek van Alphen; Hilde E Smith
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

7.  Miniaturization of three carbohydrate analyses using a microsample plate reader.

Authors:  J D Fox; J F Robyt
Journal:  Anal Biochem       Date:  1991-05-15       Impact factor: 3.365

8.  Immunogenicity of murein-associated proteins from temperature-stressed Streptococcus suis cultures.

Authors:  L Benga; R Goethe; E Grosse Beilage; P Valentin-Weigand
Journal:  J Vet Med B Infect Dis Vet Public Health       Date:  2004-08

9.  Comparative evaluation of virulence and pathology of Streptococcus suis serotypes 2 and 9 in experimentally infected growers.

Authors:  Andreas Beineke; Katharina Bennecke; Christina Neis; Charlotte Schröder; Karl-Heinz Waldmann; Wolfgang Baumgärtner; Peter Valentin-Weigand; Christoph Georg Baums
Journal:  Vet Microbiol       Date:  2007-11-04       Impact factor: 3.293

10.  The type-specific polysaccharides of Streptococcus suis.

Authors:  S D Elliott; J Y Tai
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  33 in total

1.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

2.  Role of capsule and suilysin in mucosal infection of complement-deficient mice with Streptococcus suis.

Authors:  Maren Seitz; Andreas Beineke; Alena Singpiel; Jörg Willenborg; Pavel Dutow; Ralph Goethe; Peter Valentin-Weigand; Andreas Klos; Christoph G Baums
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Immunogenicity of an autogenous Streptococcus suis bacterin in preparturient sows and their piglets in relation to protection after weaning.

Authors:  Christoph Georg Baums; Christian Brüggemann; Christoph Kock; Andreas Beineke; Karl-Heinz Waldmann; Peter Valentin-Weigand
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

4.  Antibody response specific to the capsular polysaccharide is impaired in Streptococcus suis serotype 2-infected animals.

Authors:  Cynthia Calzas; Paul Lemire; Gael Auray; Volker Gerdts; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

5.  Factors contributing to mortality during a Streptoccocus suis outbreak in nursery pigs.

Authors:  Danielle Hopkins; Zvonimir Poljak; Abdolvahab Farzan; Robert Friendship
Journal:  Can Vet J       Date:  2018-06       Impact factor: 1.008

6.  TroA of Streptococcus suis is required for manganese acquisition and full virulence.

Authors:  Paul J Wichgers Schreur; Johanna M J Rebel; Mari A Smits; Jos P M van Putten; Hilde E Smith
Journal:  J Bacteriol       Date:  2011-07-22       Impact factor: 3.490

7.  Identification of a novel host-specific IgM protease in Streptococcus suis.

Authors:  Jana Seele; Alena Singpiel; Christian Spoerry; Ulrich von Pawel-Rammingen; Peter Valentin-Weigand; Christoph G Baums
Journal:  J Bacteriol       Date:  2012-12-14       Impact factor: 3.490

8.  Group B Streptococcus and Streptococcus suis capsular polysaccharides induce chemokine production by dendritic cells via Toll-like receptor 2- and MyD88-dependent and -independent pathways.

Authors:  Cynthia Calzas; Guillaume Goyette-Desjardins; Paul Lemire; Fleur Gagnon; Claude Lachance; Marie-Rose Van Calsteren; Mariela Segura
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

9.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

10.  In vivo oxygen measurement in cerebrospinal fluid of pigs to determine physiologic and pathophysiologic oxygen values during CNS infections.

Authors:  Nicole de Buhr; Alexander Martens; Marita Meurer; Marta C Bonilla; Franz Söbbeler; Lara Twele; Stephan Neudeck; Michael Wendt; Andreas Beineke; Sabine Kästner; Maren von Köckritz-Blickwede
Journal:  BMC Neurosci       Date:  2021-06-28       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.